IBFAR2

  • 1 lab in 1 country
  • Funder: National Natural Science Foundation of China
  • Animals1

Outcomes

1

CD8+ T cell antitumor activity

upin mice1

1 study
  1. IBFAR2 improves CD8+ T cell antitumor activity in mice.

    “treatment with our developed BFAR inhibitor, iBFAR2, rescued the antitumor activity of aged CD8+ T cells by restoring TRM generation”

    Animalsmouse tumor modelsCD8+ T cells

    Age-related decline in CD8⁺ tissue resident memory T cells compromises antitumor immunity

    Nature aging26 Nov 2024

Latest